Comparative Pharmacology
Head-to-head clinical analysis: EC NAPROSYN versus FLURBIPROFEN SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EC NAPROSYN versus FLURBIPROFEN SODIUM.
EC-NAPROSYN vs FLURBIPROFEN SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Naproxen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) enzymes, thereby reducing prostaglandin synthesis, which mediates inflammation, pain, and fever.
Non-selective cyclooxygenase (COX-1 and COX-2) inhibitor, thereby decreasing prostaglandin synthesis, which mediates inflammation, pain, and fever.
500-1000 mg orally twice daily; maximum 1500 mg/day.
50 mg orally every 4 to 6 hours as needed; maximum 300 mg per day.
None Documented
None Documented
Terminal elimination half-life 12-17 hours (mean 14 hours); prolonged in elderly and renal impairment
3-4 hours; in elderly or hepatic impairment may extend to 5-6 hours.
Renal (95%) as unchanged drug (10%) and conjugated metabolites (60%) and other metabolites (25%); biliary/fecal (5%)
Renal: 70% as conjugates (glucuronide) and unchanged drug (<1%); biliary/fecal: minimal.
Category C
Category D/X
NSAID
NSAID